SG11202011461TA - Anti-pvrig/anti-tigit bispecific antibodies and methods of use - Google Patents
Anti-pvrig/anti-tigit bispecific antibodies and methods of useInfo
- Publication number
- SG11202011461TA SG11202011461TA SG11202011461TA SG11202011461TA SG11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA SG 11202011461T A SG11202011461T A SG 11202011461TA
- Authority
- SG
- Singapore
- Prior art keywords
- pvrig
- methods
- bispecific antibodies
- tigit bispecific
- tigit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862679703P | 2018-06-01 | 2018-06-01 | |
US201862773586P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/035062 WO2019232484A1 (en) | 2018-06-01 | 2019-05-31 | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011461TA true SG11202011461TA (en) | 2020-12-30 |
Family
ID=67003669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011461TA SG11202011461TA (en) | 2018-06-01 | 2019-05-31 | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190382477A1 (en) |
EP (1) | EP3802605A1 (en) |
JP (1) | JP2021525087A (en) |
KR (1) | KR20210016448A (en) |
CN (1) | CN113039202A (en) |
AU (1) | AU2019276578A1 (en) |
BR (1) | BR112020024249A2 (en) |
CA (1) | CA3101019A1 (en) |
CL (1) | CL2020003127A1 (en) |
CO (1) | CO2020016619A2 (en) |
IL (1) | IL279053A (en) |
MX (1) | MX2020012797A (en) |
SG (1) | SG11202011461TA (en) |
WO (1) | WO2019232484A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019407814A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/IL-7 molecule |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Ose Immunotherapeutics | Bifunctional molecules comprising an IL-7 variant |
TW202144417A (en) | 2020-03-13 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pvrig binding protein and its medical uses |
CN115943312A (en) | 2020-05-07 | 2023-04-07 | 法国居里学院 | Biomarker ANTXR1 of immunosuppressive fibroblast population and its use in predicting response to immunotherapy |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
WO2022165275A2 (en) * | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
WO2022165266A1 (en) * | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
WO2022171080A1 (en) * | 2021-02-09 | 2022-08-18 | 上海君实生物医药科技股份有限公司 | Anti-cd112r antibody and use thereof |
JP2024507124A (en) | 2021-02-11 | 2024-02-16 | ネクチン セラピューティクス リミテッド | Antibodies against CD112R and uses thereof |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
CN115010800A (en) * | 2021-06-10 | 2022-09-06 | 百奥赛图(北京)医药科技股份有限公司 | Construction method and application of PVRIG gene humanized non-human animal |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
CA3227972A1 (en) * | 2021-07-30 | 2023-02-02 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibodies and applications thereof |
CN117940453A (en) * | 2021-09-15 | 2024-04-26 | 江苏恒瑞医药股份有限公司 | Protein capable of specifically binding to PD-1 and medical application thereof |
CA3231553A1 (en) * | 2021-09-15 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
CN114057867B (en) * | 2021-12-14 | 2023-05-12 | 河南联科物联网科技有限公司 | Monoclonal antibody for resisting egg drop syndrome and application thereof |
CN116925233A (en) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | anti-TIGIT-anti-PVRIG bispecific antibody, pharmaceutical composition and use thereof |
CN116925222A (en) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | anti-PVRIG antibody, pharmaceutical composition and application thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023236980A1 (en) * | 2022-06-08 | 2023-12-14 | 山东先声生物制药有限公司 | Pharmaceutical composition of pvrig/tigit bispecific antibody and use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
MXPA01007170A (en) | 1999-01-15 | 2002-07-30 | Genentech Inc | Polypeptide variants with altered effector function. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
BR0213761A (en) | 2001-10-25 | 2005-04-12 | Genentech Inc | Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition |
US7139665B2 (en) | 2002-02-27 | 2006-11-21 | California Institute Of Technology | Computational method for designing enzymes for incorporation of non natural amino acids into proteins |
WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
EP1675620B1 (en) | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
KR20070007086A (en) | 2004-02-02 | 2007-01-12 | 암브룩스, 인코포레이티드 | Modified human four helical bundle polypeptides and their uses |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
EP2975051B1 (en) | 2009-06-26 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
PT2838918T (en) | 2012-04-20 | 2019-08-23 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
EP2858673A4 (en) * | 2012-06-06 | 2016-06-22 | Oncomed Pharm Inc | Binding agents that modulate the hippo pathway and uses thereof |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
CA2902739C (en) | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
EP3021869B1 (en) | 2013-07-16 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
ME03666B (en) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
MA40475A (en) | 2014-08-19 | 2017-06-28 | Fayadat Dilman Laurence | Anti-tigit antibodies |
AU2015369683B2 (en) | 2014-12-23 | 2020-12-10 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
DK3295951T3 (en) | 2015-02-19 | 2020-07-20 | Compugen Ltd | ANTI-PVRIG ANTIBODIES AND METHODS OF USE |
EP4223784A3 (en) | 2015-09-02 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | Compositions and methods for modulating t-cell mediated immune response |
PL3356413T3 (en) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
RU2022104399A (en) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS |
WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
MY194032A (en) | 2016-08-17 | 2022-11-09 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11225523B2 (en) * | 2017-06-01 | 2022-01-18 | Compugen Ltd. | Triple combination antibody therapies |
-
2019
- 2019-05-31 SG SG11202011461TA patent/SG11202011461TA/en unknown
- 2019-05-31 WO PCT/US2019/035062 patent/WO2019232484A1/en active Application Filing
- 2019-05-31 EP EP19733259.6A patent/EP3802605A1/en active Pending
- 2019-05-31 BR BR112020024249-7A patent/BR112020024249A2/en unknown
- 2019-05-31 CN CN201980050598.6A patent/CN113039202A/en active Pending
- 2019-05-31 KR KR1020207038135A patent/KR20210016448A/en unknown
- 2019-05-31 US US16/428,856 patent/US20190382477A1/en active Pending
- 2019-05-31 JP JP2020565487A patent/JP2021525087A/en active Pending
- 2019-05-31 MX MX2020012797A patent/MX2020012797A/en unknown
- 2019-05-31 AU AU2019276578A patent/AU2019276578A1/en active Pending
- 2019-05-31 CA CA3101019A patent/CA3101019A1/en active Pending
-
2020
- 2020-11-29 IL IL279053A patent/IL279053A/en unknown
- 2020-12-01 CL CL2020003127A patent/CL2020003127A1/en unknown
- 2020-12-30 CO CONC2020/0016619A patent/CO2020016619A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019232484A1 (en) | 2019-12-05 |
BR112020024249A2 (en) | 2021-03-02 |
KR20210016448A (en) | 2021-02-15 |
WO2019232484A9 (en) | 2021-05-06 |
CL2020003127A1 (en) | 2021-10-29 |
IL279053A (en) | 2021-01-31 |
MX2020012797A (en) | 2021-03-25 |
JP2021525087A (en) | 2021-09-24 |
CA3101019A1 (en) | 2019-12-05 |
AU2019276578A1 (en) | 2021-01-14 |
US20190382477A1 (en) | 2019-12-19 |
CN113039202A (en) | 2021-06-25 |
EP3802605A1 (en) | 2021-04-14 |
CO2020016619A2 (en) | 2021-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279053A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use | |
IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
HUE062927T2 (en) | Anti-tigit antibodies and methods of use thereof | |
IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
HUE062436T2 (en) | Anti-trem2 antibodies and methods of use thereof | |
IL278772A (en) | Anti-ox40 antibodies and methods of use | |
IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
IL277212A (en) | Anti-klk5 antibodies and methods of use | |
IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
IL287282A (en) | Anti-mertk antibodies and their methods of use | |
SG11202106498XA (en) | Anti-ctla4 antibodies and methods of use thereof | |
IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
EP4061848A4 (en) | Anti-ror-2 antibodies and methods of use | |
EP3994174A4 (en) | Monospecific anti-frizzled antibodies and methods of use | |
IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
IL271346A (en) | Bispecific antibodies and methods of making and using thereof | |
SG11202113221RA (en) | Anti-cd137l antibodies and methods of using same |